FDA Peptide Tracker

Retatrutide: live FDA regulatory status

Triple GLP-1/GIP/glucagon · Investigational

The two signals

Plain-English verdict: amber.

Regulatory status: Investigational (Phase 3).

These two never collapse into one. Removal from a list is not the same as legal-to-compound, and neither is the same as available.

Availability at Peptós.LIFE

Join waitlist

What Retatrutide is

An investigational triple GLP-1/GIP/glucagon agonist posting the largest weight-loss numbers recorded so far.

Short version: the molecule the metabolic world is watching hardest. Phase-3 trial figures lead the category, but it is investigational, not approved, and not something anyone can legitimately get yet.

Retatrutide is the molecule that owns the next GLP-1 headline. We build the education and the waitlist now, and we are clear that 'best trial numbers' is not the same as 'you can get it.'

Why it sits in this category

Retatrutide is tracked under Investigational. Its regulatory status is Investigational (Phase 3) — a separate signal from whether you can actually get it today. We never collapse the two.

Not available to prescribe. Retatrutide is an investigational drug in Phase-3 trials (Eli Lilly), not FDA-approved, not compoundable, and heavily counterfeited on the grey market. We track it and capture demand honestly; we make no availability promise.

A single molecule agonizing three receptors, GLP-1, GIP, and glucagon, combining appetite suppression with an added energy-expenditure signal from glucagon.

What it does — and what it does not do

What it does: In trials, drives the largest average body-weight reduction seen to date for the class (reported ~24–29%).

What it does not do: It is not approved, not available, and not a guaranteed result; trial figures are not a promise and grey-market product is unverified and unsafe.

What would have to change

Next milestone on the regulatory path: TRIUMPH Phase-3 readout (projected) — 2026–2027. A favorable advisory (PCAC) vote is a recommendation that leads to rulemaking — not FDA approval, not authorization to compound, and not availability.

Evidence grade

Grade B — large Phase-3 trial data (TRIUMPH), figures pending peer review; re-verify. See our grading methodology for what each grade means.

What we still don't know: Long-term safety and durability are not yet established; the trial program is ongoing and figures may change at peer review and approval.

Regulatory timeline

PCAC is advisory: its Jul 2026 recommendation leads to rulemaking, not instant availability. A favorable advisory vote is a recommendation, not FDA approval or authorization to compound. Realistic earliest legitimate access is late 2026 into 2027. Reclassification is not the same as FDA approval. Compounded medications are not evaluated or approved by the FDA for safety, efficacy, or quality, where that applies, we say so, plainly.

Primary source: FDA source record

See the full status board or this molecule's knowledge-base monograph.

Last updated July 26, 2026 · Peptós.LIFE · Not medical advice.